Clinicopathological features of cutaneous and renal glomerular vasculopathy in 178 dogs.

BACKGROUND: One hundred seventy-eight dogs with cutaneous and renal glomerular vasculopathy (CRGV) were evaluated to further the understanding of the natural course of CRGV. CRGV, a form of thrombotic microangiopathy, can cause skin lesions and potentially acute kidney injury (AKI) with a high mortality rate. METHODS: Cases were submitted from multiple practices from 2012 until June 2019. Clinical histories and laboratory data were reviewed to describe the features of CRGV. RESULTS: Most cases (91%) occurred between November and May. Fifteen dogs (8.4%) with CRGV were in contact with another dog that developed skin lesions +/- AKI. Limb lesions were present on 144 dogs (80.9%) at presentation. Median time from appearance of a lesion to AKI was 3 days (range -4-45 days). Neurological signs occurred in 33 dogs (18.6%) including at presentation in 2 (1.1%). Systemic signs were present in 13 dogs prior to a skin lesion (7.3%). Non-steroidal anti-inflammatory drugs were prescribed prior to AKI identification in 92 of 170 dogs (54.1%). Thrombocytopenia was present in 115 of 137 (83.9%) of dogs. CONCLUSION: The timeframe over which AKI may develop is longer than previously reported, neurological signs can be identified at presentation or during hospitalisation, and thrombocytopenia is even more common than previously reported.

Establishing levels of retained radioactivity in cats receiving radioactive iodine treatment.

BACKGROUND: Radioactive iodine (RAI) is considered the gold standard treatment for feline hyperthyroidism. Currently exposure limits to radiation are regulated by national legislation, therefore the length of the isolation period in hospital for cats receiving radioactive treatment varies according to the place where the radioactive facility is located. The aim of this study was to establish when retained radioactivity decreases in cats receiving subcutaneous I-131 to a level that would allow discharge of cats from the hospital while being compliant with current United Kingdom legislation. METHODS: Clinical records of cats treated with subcutaneous I-131 were retrospectively reviewed. Radioactive emission rates were measured using an external probe. Retained radioactivity below 11 MBq at the point of discharge was required by the initial risk assessment to ensure that a 0.3 mSv dose constraint was maintained for owners following standard cat-owner contact restrictions. Average retained activity for each treatment regimen at the time of discharge was calculated. The biological half-life for iodine retention was also calculated. RESULTS: Overall, an end activity below 11 MBq was reached at day 11 in 49% of cats, and at day 13 in 91% of cats. These cats were allowed to be discharged according to UK legislation, as long as contact restrictions were applied at home for 2 weeks. CONCLUSION: Based on our study, an isolation period of 13 days before allowing discharge of cats treated with subcutaneous RAI (I-131) is compliant with current UK legislation.

Spatiotemporal patterns and agroecological risk factors for cutaneous and renal glomerular vasculopathy (Alabama Rot) in dogs in the UK.

The annual outbreaks of cutaneous and renal glomerular vasculopathy (CRGV) reported in UK dogs display a distinct seasonal pattern (November to May) suggesting possible climatic drivers of the disease. The objectives of this study were to explore disease clustering and identify associations between agroecological factors and CRGV occurrence. Kernel-smoothed maps were generated to show the annual reporting distribution of CRGV, Kuldorff's space-time permutation statistic used to identify significant spatiotemporal case clusters and a boosted regression tree model developed to quantify associations between CRGV case locations and a range of agroecological factors. The majority of diagnoses (92 per cent) were reported between November and May while the number of regions reporting the disease increased between 2012 and 2017. Two significant spatiotemporal clusters were identified-one in the New Forest during February and March 2013, and one adjacent to it (April 2015 to May 2017)-showing significantly higher and lower proportions of cases than the rest of the UK, respectively, for the indicated time periods. A moderately significant high-risk cluster (P=0.087) was also identified in the Manchester area of northern England between February and April 2014. Habitat was the predictor with the highest relative contribution to CRGV distribution (20.3 per cent). Cases were generally associated with woodlands, increasing mean maximum temperatures in winter, spring and autumn, increasing mean rainfall in winter and spring and decreasing cattle and sheep density. Understanding of such factors may help develop causal models for CRGV occurrence.

Signalment risk factors for cutaneous and renal glomerular vasculopathy (Alabama rot) in dogs in the UK.

Seasonal outbreaks of cutaneous and renal glomerular vasculopathy (CRGV) have been reported annually in UK dogs since 2012, yet the aetiology of the disease remains unknown. The objectives of this study were to explore whether any breeds had an increased or decreased risk of being diagnosed with CRGV, and to report on age and sex distributions of CRGV cases occurring in the UK. Multivariable logistic regression was used to compare 101 dogs diagnosed with CRGV between November 2012 and May 2017 with a denominator population of 446,453 dogs from the VetCompass database. Two Kennel Club breed groups-hounds (odds ratio (OR) 10.68) and gun dogs (OR 9.69)-had the highest risk of being diagnosed with CRGV compared with terriers, while toy dogs were absent from among CRGV cases. Females were more likely to be diagnosed with CRGV (OR 1.51) as were neutered dogs (OR 3.36). As well as helping veterinarians develop an index of suspicion for the disease, better understanding of the signalment risk factors may assist in the development of causal models for CRGV and help identify the aetiology of the disease.

Determining resolution of Angiostrongylus vasorum in dogs following anthelmintic treatment with an imidacloprid 10 per cent/moxidectin 2.5 per cent spot-on.

OBJECTIVES: To determine the time from treatment with a product containing imidacloprid 10 per cent/moxidectin 2.5 per cent spot-on (Advocate™), to dogs becoming negative for Angiostrongylus vasorum (A. vasorum). The authors hypothesised that most dogs would have resolution of A. vasorum within four weeks of treatment with Advocate™. DESIGN: Prospective, non-randomised, prepost treatment study. SETTING: Cases were enrolled from general practices along the southern coast of the United Kingdom. PARTICIPANTS: Nine dogs completed the study and were enrolled if A. vasorum had been diagnosed based on a positive commercially available, in-clinic, serological A. vasorum antigen test (Angio Detect®) or Baermann performed at an external laboratory or both. INTERVENTIONS: The only treatment A. vasorum-positive dogs received was Advocate™ which was applied at the time of diagnosis and reapplied if necessary at four-weekly intervals until dogs tested negative by Angio Detect. PRIMARY OUTCOME MEASURES: Angio Detect® was performed and Advocate™ was reapplied at four-weekly intervals until dogs tested negative by this method. SECONDARY OUTCOME MEASURES: Baermann was also performed at four-weekly intervals until dogs tested negative by this method. RESULTS: Application of Advocate™ was an effective treatment for A. vasorum infection in dogs and resulted in resolution of the infection, based on Angio Detect® testing and Baermann, within four weeks, in eight out of nine dogs. Post-treatment Angio Detect® testing was concordant with Baermann in seven of nine dogs. CONCLUSIONS: Application of Advocate™ was an effective treatment for A. vasorum infection in dogs and resulted in resolution of the infection within four weeks in most dogs. Repeat Angio Detect® testing is recommended following treatment of A. vasorum to confirm resolution of the infection.